EVIDENCE BASED DECISION MAKING FOR THE RATIONAL DRUG LIST (RDL) DR MAISA AL SAKET DG JOINT PROCUREMENT DEPARTMENT Committee 2 Evidence Based MeTA 10/06/09

Members of Committee 2 Dr Maisa Al Saket/ G.D. - JPD Dr Riham Al Natheef/ Supply Director- RMS Dr Musallam Qatarneh/ Purchasing & Supply Director/ MOH Dr Ibrahim Abbadi/ Jordan University Dr Lama Al Homoud/ Clinical Pharmacy Director - MOH Dr Hanan Sboul/ SG. - JAPM 10/06/09 MeTA

Dr Maisa Al Saket/ G.D. - JPD

Dr Riham Al Natheef/ Supply Director- RMS

Dr Musallam Qatarneh/ Purchasing & Supply Director/ MOH

Dr Ibrahim Abbadi/ Jordan University

Dr Lama Al Homoud/ Clinical Pharmacy Director - MOH

Dr Hanan Sboul/ SG. - JAPM

Background There will be a transparent evidence- based process in place for listing drugs Conducting Pharmaco-economic studies is crucial for the development of an effective and affordable national drug list It is crucial that the public health institutions are supportive of the process and believe in the integrity of the final RDL in order to promote the adherence to it by prescribers and institutions 10/06/09 MeTA

There will be a transparent evidence- based process in place for listing drugs

Conducting Pharmaco-economic studies is crucial for the development of an effective and affordable national drug list

It is crucial that the public health institutions are supportive of the process and believe in the integrity of the final RDL in order to promote the adherence to it by prescribers and institutions

MeTA Work plan- Jordan Encouraging best practice/ improve rational use of medicines Evidence based decision making for the rational drug list RDL Capacity building in Civil society 10/06/09 MeTA

Encouraging best practice/ improve rational use of medicines

Evidence based decision making for the rational drug list RDL

Capacity building in Civil society

Evidence- based decision making can be achieved through: Assessment of Current Committees’ constitution, TOR and Procedures Assessment of current classification of drugs Raising awareness among stakeholders and building capacity Monitoring & evaluation 10/06/09 MeTA

Assessment of Current Committees’ constitution, TOR and Procedures

Assessment of current classification of drugs

Raising awareness among stakeholders and building capacity

Monitoring & evaluation

Assessment of Current Committees’ constitution, TOR and Procedures sub-activities: Review constitutions, TOR and SOPs of various committees involved in the selection of drugs in the RDL (requires COI declaration, and COI guidelines) and benchmark against best practices Recommend regulations for the amendments- if needed Review criteria for adding and deleting drugs to and from the RDL Recommend evidence based regulations for the addition / deletion criteria Adopt the recommendations 10/06/09 MeTA

Review constitutions, TOR and SOPs of various committees involved in the selection of drugs in the RDL (requires COI declaration, and COI guidelines) and benchmark against best practices

Recommend regulations for the amendments- if needed

Review criteria for adding and deleting drugs to and from the RDL

Recommend evidence based regulations for the addition / deletion criteria

Adopt the recommendations

Assessment of current classification of drugs Formulate a technical working group to review the classification of drugs (restricted, unrestricted & authority required) in the RDL Recommend detailed evidence based regulations for the implementation of the classification of drugs Adopt the classification & the detailed regulations for the implementation of the classification 10/06/09 MeTA

Formulate a technical working group to review the classification of drugs (restricted, unrestricted & authority required) in the RDL

Recommend detailed evidence based regulations for the implementation of the classification of drugs

Adopt the classification & the detailed regulations for the implementation of the classification

Technical working group represents JFDA/ RDU JPD Ministry of Health/ Clinical Pharmacy , Supply Departments Royal Medical Services/ Drug &Pharmacy, Supply Departments Academia/ PhD in clinical pharmacy Internal medicine consultant Pharmaco-economist 10/06/09 MeTA

JFDA/ RDU

JPD

Ministry of Health/ Clinical Pharmacy , Supply Departments

Royal Medical Services/ Drug &Pharmacy, Supply Departments

Academia/ PhD in clinical pharmacy

Internal medicine consultant

Pharmaco-economist

Raising awareness among stakeholders and building capacity Organize workshops to raise awareness and reach a common understanding on the concepts of role of pharmacy & therapeutic committee (PTC), evidence-based medicine (EBM), pharmaco-economics, transparency & accountability Train policy makers and technical committees in NICE/UK Organize workshop on use of cost effectiveness tools 10/06/09 MeTA

Organize workshops to raise awareness and reach a common understanding on the concepts of role of pharmacy & therapeutic committee (PTC), evidence-based medicine (EBM), pharmaco-economics, transparency & accountability

Train policy makers and technical committees in NICE/UK

Organize workshop on use of cost effectiveness tools

Monitoring and Evaluation Monitor and Evaluate the adoption and implementation of recommendations in previous activities, according to set KPI’s 10/06/09 MeTA

Monitor and Evaluate the adoption and implementation of recommendations in previous activities, according to set KPI’s

Evidence- based decision making activities KPI’s include: Constitution, TOR & SOPs for committees are in place Guidelines for addition/ deletion & classification are in place Workshops conducted Reports to be delivered 10/06/09 MeTA

Constitution, TOR & SOPs for committees are in place

Guidelines for addition/ deletion & classification are in place

Workshops conducted

Reports to be delivered

Thank you 10/06/09 MeTA